Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS).
Corinna G V Slawinski, Lee Malcomson, Jorge Barriuso et al.
✦ AI-curated · Sources linked
In 30 seconds
This individual participant data meta-analysis examined the relationship between body mass index (BMI) and survival in 7264 patients with non-metastatic colorectal cancer undergoing adjuvant chemotherapy. The study found that a 5 kg/m² increase in BMI was associated with a significant reduction in average cumulative relative dose of chemotherapy (-1.15%), while improved average relative dose intensity correlated with better overall survival (HR 0.94).
Key findings
- A 5 kg/m² increase in BMI led to a significant reduction in average cumulative relative dose of chemotherapy (-1.15%).
- An increase of 5% in average relative dose intensity was associated with improved overall survival (HR 0.94).
- Toxicity was linked to worse overall survival (TE HR 1.37), but this effect was attenuated when adjusting for average cumulative relative dose.
- BMI showed no association with grade 3+ toxicity (OR 1.01).
Why it matters
Understanding the impact of BMI on chemotherapy dosing and survival outcomes is crucial for optimizing treatment strategies in colorectal cancer. This study highlights the importance of full dosing based on body surface area to potentially improve survival rates.